You are here » Home » Companies » Company Overview » Jubilant Ingrevia Ltd

Jubilant Ingrevia Ltd.

BSE: 543271 Sector: Industrials
NSE: JUBLINGREA ISIN Code: INE0BY001018
BSE 12:29 | 09 Dec 533.10 13.40
(2.58%)
OPEN

520.05

HIGH

539.75

LOW

519.70

NSE 12:14 | 09 Dec 532.85 13.90
(2.68%)
OPEN

521.55

HIGH

539.75

LOW

520.00

OPEN 520.05
PREVIOUS CLOSE 519.70
VOLUME 47068
52-Week high 647.50
52-Week low 401.35
P/E 25.10
Mkt Cap.(Rs cr) 8,492
Buy Price 533.20
Buy Qty 9.00
Sell Price 533.45
Sell Qty 10.00
OPEN 520.05
CLOSE 519.70
VOLUME 47068
52-Week high 647.50
52-Week low 401.35
P/E 25.10
Mkt Cap.(Rs cr) 8,492
Buy Price 533.20
Buy Qty 9.00
Sell Price 533.45
Sell Qty 10.00

Jubilant Ingrevia Ltd. (JUBLINGREA) - Chairman Speech

Company chairman speech

Dear shareholders

FY 2022 has been a very rewarding year as the Company registered astellar performance despite the challenges that surfaced across the year. Our strongpresence in diversified segments of the life science industry coupled with more than fourdecades of experience in Research & Development and manufacturing firmly placed us onthe growth journey where the destination is excellence and beyond.

Our dedicated employees (over 2100) across the globe played afundamental role in our stellar performance. Their critical role in _ghting thedevastating second wave of COVID-19 by supporting each other both physically andemotionally contributed to running business operations smoothly and servicing ourcustomers timely. The teams' patient perseverance and disciplined dedication haspositioned Jubilant Ingrevia Limited as the ‘Partner of Choice'for the leadingPharmaceuticals Agrochemicals and other global companies.

Revenue from operations recorded a 42% rise year-on-year EBITDAregistered a jubilating rise of 38% as did the Profit after Tax growth of 51% over FY2021. These growth numbers were achieved despite enduring the second wave of the pandemicand significant volatility in key raw material and energy prices almost throughout thefinancial year.

Our Speciality Chemicals segment has catalysed the growth through ourunwavering commitment to delivery coupled with a healthy demand across industry segmentsglobally. We are also pleased to share that we successfully commissioned Phase-1 of theDiketene Derivatives plant at our Gajraula manufacturing facility.

In our Nutrition & Health Solutions segment we improved ourprofitability owing to superior price realisation as well as improved volumes. Ourcontinued focus on improving our performance in niche segment of Vitamin B3 i.e foodpharma and cosmetics have also played key role in spurring the gowth in the segment.

In the Chemical Intermediates segment we could easily service all theincreased demand of Acetic Anhydride for the Paracetamol production in India and inInternational market. Our new expanded capacity in last financial year was utilised wellin servicing this increased volume in the segment. Overall the segment has seen higherdemand in Pharmaceuticals Agrochemicals and other end usage across the globe.

We are glad to share that the Board has recommended overall 500%dividend in FY 2022. During the year the Company declared an interim dividend of 250%i.e. Rs 2.5 per equity share of Rs 1 each and then a final dividend of 250% i.e. Rs 2.5per equity share of face value of Rs 1 each for the FY 2022. This has resulted in cashoutflow to Rs 796 million in FY 2022 ie Rs 5.00 (500%) per equity share of Rs 1.

We take this opportunity to convey that this growth trajectory is not aone-time event that Jubilant Ingrevia wishes to settle for. Considering what we have setour eyes on the FY 2022 achievements will dwarf into a prelude to an even more jubilantfuture. We are investing Rs 20500 million in the business between FY 2022 to FY 2025 in aphased manner. This investment is mainly in the various growth related projects of newproduct platforms as well as new business areas in addition to optimising the existingcapacities to take care of growing demand of existing products. This plan will unfold in aphased manner until FY 2025. It showcases our strong resolve to excel and keep betteringour results.

Some of these investments have already been committed and newfacilities have been commissioned. The newly commissioned Diketene Derivatives plant atour Gajraula manufacturing facility is the beginning of our new product portfolio ofDiketene range of value added products. It will position us to replicate our great workalready done in Pyridine platform by bringing in several value-added products using morethan 30 chemistry capabilities. It will also help us in getting additional business fromour time-tested association with leading customers in Pharmaceuticals Agrochemicals andother industries.

Our products touch everyone in their daily lives directly orindirectly hence creating a demand for our products. Moreover as economies stabilise ina post-pandemic world consumption is expected to rise driving the demand for SpecialityChemicals and Nutrition & Health Solutions.

As the world focuses on widening their supplier base to de-risk fromgeographic concentration India owing to its acumen in the Speciality Chemicals &CDMO space its competitiveness and its experience in dealing with global partners isgaining the global spotlight. Our leadership position in select products multi-decadalhealthy business relations with large international corporates perfectly positions us tocapitalise on the growing opportunities.

The prospects of the domestic market place appear equally exciting.According to a recent United Nations report India is expected to surpass China as theworld's most populous country in 2030. The resultant creeping demand for our productsis expected to leapfrog to a new level.

In keeping with these trends it was necessary to make this sizeableinvestment which promises to strengthen our competitive advantage with theircommissioning.

Our expansions will not simply increase the output numbers. They arevalue-added diversifications. Because we foresaw the future for the world and envisionednew age requirements. Moreover we have platformed our investments on the sustainablestructure. As a result our future-focused endeavours are well-thought-out plans

_ltered on the sustainability mesh allowing us to help our customersmeet their sustainability commitments. This strategy will help us cement a lasting bondwith our customers – existing and prospective.

We are fully committed towards our growth aspirations and we areexcited to realise the emerging opportunities going forward in all our business segments.We are confident of moving ahead with our well defined strategic capex blueprint which issupported by our internal accruals. Our aim is to achieve sustainable profitable growth inmedium term and structurally we are poised towards moving on to the next tier ofperformance in our growth journey and margins

We thank all our employees for demonstrating resilience in times ofhardships and challenges and for supporting the Company. We also would like to take thisopportunity to thank our Board of Directors for their constant guidance and suggestions.Our gratitude to every stakeholder including our customers vendors and bankers whobelieved in us. We continue to solicit your trust.

Warm regards
Shyam S. Bhartia Hari S. Bhartia
Chairman Co-Chairman

.